Related Experiment Video
Updated: Jan 17, 2026

Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
Multisystem embolism in hereditary protein C deficiency with patent foramen ovale: a case report
Lihua Chen1, Jianhua Guan2, Yunfeng Ni3
1Department of Encephalopathy, The Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Insights
Hereditary protein C deficiency (HPCD) combined with a patent foramen ovale (PFO) can lead to dangerous multisystem embolism. Early diagnosis and combined treatment are crucial for patient recovery and preventing recurrent events.
Area of Science:
- Cardiology
- Hematology
- Genetics
Background:
- Hereditary protein C deficiency (HPCD) is a rare genetic thrombophilia.
- Patent foramen ovale (PFO) with right-to-left shunt (RLS) increases embolism risk.
- The combined effect of HPCD and PFO on multisystem embolism is unreported.
Abstract:
Hereditary protein C deficiency (HPCD) is a rare autosomal dominant thrombophilia caused by PROC gene mutations, predisposing patients to venous thrombosis. Patent foramen ovale (PFO) with right-to-left shunt (RLS) may facilitate paradoxical embolism, increasing the risk of stroke and pulmonary embolism. However, the coexistence of HPCD and PFO leading to multisystem embolism has not been previously reported. We report a 29-year-old woman presenting with sudden-onset altered consciousness. The patient had no traditional cerebrovascular risk factors other than oral contraceptive use. Imaging revealed basilar artery occlusion, left pulmonary embolism, and bilateral iliac vein thrombosis. Laboratory testing demonstrated reduced protein C activity, and genetic analysis identified a heterozygous pathogenic PROC variant (c.541T>G, p.Phe181Val). Transcranial Doppler bubble study, transesophageal echocardiography (TEE), and agitated saline contrast echocardiography (ASCE) confirmed a PFO with grade 3 RLS. The patient was diagnosed with HPCD combined with PFO. She underwent emergent mechanical thrombectomy, inferior vena cava (IVC) filter placement, subsequent PFO closure, and lifelong rivaroxaban therapy. At 1-year follow-up, she exhibited excellent clinical recovery with complete resolution of symptoms and no evidence of recurrent thromboembolic events. This first-reported case highlights the potential synergistic thrombotic risk of coexisting HPCD and PFO. For patients with unexplained multisystem embolism, thorough evaluation of both conditions is essential, and individualized comprehensive treatment strategies are crucial for a good prognosis.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism III: Nursing Management
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Mitral Stenosis I: Introduction
Aneurysm II: Clinical Manifestations and Diagnostic Studies

